Human Organoids Market

The human organoids market size will be USD 2.33 billion by 2029, from USD 1.19 billion in 2024, at a CAGR of 14.4% during the forecast period. Major growth drivers in the market include a growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of human organoids, and increasing research activities on organoids. Human organoid technologies are increasingly  being adopted as its interest continues to grow into research, since it is serving as an ethical and an effective alternative for animal testing models. The increasing funding and attention towards organoid technology is boosting its adoption in pharmaceutical development and disease modeling. These factors supports the growth of organoid applications within the personal medicine area and toxicology testing. Altogether, these factors add up to the global rising need for human organoids.

The key players in this market are Thermo Fisher Scientific Inc. (US), Corning Incorporated (US), Merck KGaA (Germany), BioIVT (US), HUB Organoids BV (Netherlands), BICO (Sweden), BeCytes Biotechnologies SL (Spain), InSphero (Switzerland), GBA Group (Germany), Kirkstall Ltd. (UK), MIMETAS BV (Netherlands), Neuromics (US), PRIMACYT Cell Culture Technology GmbH (Germany), STEMCELL Technologies (Canada), ACROBiosystems (China), Biopredic International (France), CN Bio Innovations Ltd. (UK), CYPRIO (France), Emulate, Inc. (US), Kerafast, Inc. (US), Pandorum Technologies Pvt. Ltd (India), CYFUSE BIOMEDICAL K.K. (Japan), NeyroblastGX LLC (US), 3Dnamics Inc. (US), and DefiniGEN Limited (UK). The market players have adopted various strategies such as development of advanced products, partnerships, expansions, and acquisitions to strengthen their position in the human organoids. The organic and inorganic strategies have helped the market players expand globally by providing human organoids.

To know about the assumptions considered for the study download the pdf brochure

Thermo Fisher Scientific develops and manufactures, as well as markets, analytical instruments, reagents and consumables, equipment, and software products. The company operates in four business segments: Analytical Instruments, Specialty Diagnostics, Life Sciences Solutions, and Laboratory Products and Biopharma Services. It offers human organoid products under its Life Sciences Solutions segment. The company is well presented in more than 70 countries across North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. It invests in research and development to bring out new and innovative products. In addition, it focuses on partnerships for strengthening business capabilities and enhancing market share.

Corning Incorporated is a multinational corporation based in the US, primarily focused on manufacturing of specialty glass and ceramic technology alongside other allied materials & technologies that include advanced industrial and scientific optics. The corporation operates 124 manufacturing facilities in 15 countries and is organized into five broad-based divisions. These are - the Optical Communications Division, the Display Technologies Division, the Specialty Materials Division, the Environmental Technologies Division, and the Life Sciences Division. Through the Life Sciences division, Corning manufactures human organoid products. Focused on R&D, the company is keen on rolling out new and advanced technological products. It works with a variety of partners, including research institutions and customers, to help speed up the processes of research and development. This helps build its business, improves its technologies and products, enables it to enter new markets, and nurtures relationships with customers over time.

BiolVT is a biobanking company, focused on designing, manufacturing, and providing biological specimens such as human tissues and cell products, blood, as well as other biofluids to clients across North America, Asia Pacific, Europe, and the Middle East & Africa. BiolVT is a prominent company in the human organoids market and has developed a multitude of tissue models of organs.. The portfolio is so diverse that researchers get access to models specifically customized for research purposes, such as drug testing and modeling of disease. With a global network of collection sites and collaborations, BiolVT is manufacturing organoid models compatible for diversified clinical conditions.The company focuses on Inorganic strategies to hold a strong foothold in the market.To maintain a solid presence in the industry, the company focuses on inorganic strategies. For instance, in July 2021, BiolVT acquired Tissue Solutions Ltd. virtual biobank; the acquisition expanded BiolVT's global network through the addition of 150 collection sites to the network while providing improved access to high-quality control and disease state biospecimens and increased global reach for prospective collections.

Related Reports:

Human Organoids Market by Product (Liver, Kidney, Pancreatic Models (2D, 3D)), Disease Area (Oncology, GI, Neurological Disorders), Application (Drug Toxicity, Personalized Medicine), End User (Pharma & Biotech Companies, CROs) - Global Forecast to 2029

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]